Focus Financial Network Inc. ADV Makes New Investment in Moderna, Inc. (NASDAQ:MRNA)


Focus Financial Network Inc. ADV acquired a new position in Moderna, Inc. (NASDAQ:MRNA – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 5,997 shares of the company’s stock, valued at approximately $596,000.

Other hedge funds have also recently made changes to their positions in the company. Ogorek Anthony Joseph NY ADV purchased a new stake in shares of Moderna in the fourth quarter worth about $27,000. Arlington Trust Co LLC lifted its position in shares of Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Moderna by 32.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock worth $47,000 after buying an additional 116 shares in the last quarter. Archer Investment Corp lifted its position in shares of Moderna by 71.2% in the third quarter. Archer Investment Corp now owns 534 shares of the company’s stock worth $55,000 after buying an additional 222 shares in the last quarter. Finally, Sachetta LLC purchased a new stake in shares of Moderna in the fourth quarter worth about $56,000. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 5.9 %

NASDAQ:MRNA traded down $8.94 during midday trading on Friday, hitting $142.55. The stock had a trading volume of 7,180,988 shares, compared to its average volume of 4,427,435. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47. The company has a market capitalization of $54.63 billion, a price-to-earnings ratio of -9.10 and a beta of 1.57. The stock has a 50-day moving average of $120.42 and a 200 day moving average of $103.42. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. During the same quarter in the prior year, the firm earned $0.19 earnings per share. Moderna’s revenue was down 91.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Moderna, Inc. will post -7.47 EPS for the current year.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 705 shares of Moderna stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the completion of the transaction, the chief financial officer now owns 5,048 shares in the company, valued at approximately $514,542.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Shannon Thyme Klinger sold 544 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $99.05, for a total transaction of $53,883.20. Following the sale, the insider now directly owns 9,267 shares in the company, valued at approximately $917,896.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James M. Mock sold 705 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $101.93, for a total value of $71,860.65. Following the sale, the chief financial officer now owns 5,048 shares in the company, valued at $514,542.64. The disclosure for this sale can be found here. Insiders have sold a total of 203,789 shares of company stock valued at $23,868,305 over the last quarter. 15.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of research analyst reports. UBS Group boosted their target price on Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Jefferies Financial Group restated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. HSBC restated a “reduce” rating and set a $86.00 price objective (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Royal Bank of Canada upped their price objective on Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Finally, Canaccord Genuity Group upped their price objective on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research report on Friday, May 3rd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Moderna has an average rating of “Hold” and an average target price of $126.46.

Get Our Latest Research Report on Moderna

About Moderna

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

See Also

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Before you consider Moderna, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Moderna wasn’t on the list.

While Moderna currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginners Guide To Retirement Stocks Cover

Click the link below and we’ll send you MarketBeat’s list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *